BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lawrence TS. Fluorodeoxyuridine-mediated cytotoxicity and radiosensitization require S phase progression. International Journal of Radiation Biology 2009;70:273-80. [DOI: 10.1080/095530096145003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Simpson C, Stern D. Chlamydomonas reinhardtii as a Model System for Dissecting Chloroplast RNA Processing and Decay Mechanisms. Ribonucleases - Part B. Elsevier; 2001. pp. 384-407. [DOI: 10.1016/s0076-6879(01)42561-4] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
2 Sasaki K, Tsuno NH, Sunami E, Kawai K, Shuno Y, Hongo K, Hiyoshi M, Kaneko M, Murono K, Tada N, Nirei T, Kitayama J, Takahashi K, Nagawa H. Radiosensitization of human breast cancer cells to ultraviolet light by 5-fluorouracil. Oncol Lett 2011;2:471-6. [PMID: 22866105 DOI: 10.3892/ol.2011.261] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
3 Kim S, Brown S, Kim J. The potentiation of radiation response in human colon carcinoma cells in vitro and murine lymphoma in vivo by AG337 (thymitaq™), a novel thymidylate synthase inhibitor. International Journal of Radiation Oncology*Biology*Physics 1998;42:789-93. [DOI: 10.1016/s0360-3016(98)00338-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Citrin DE, Mitchell JB. Altering the response to radiation: sensitizers and protectors. Semin Oncol 2014;41:848-59. [PMID: 25499642 DOI: 10.1053/j.seminoncol.2014.09.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
5 Molls M, Nieder C, Belka C, Norum J. Quantitative Cell Kill of Radio- and Chemotherapy. In: Molls M, Vaupel P, Nieder C, Anscher MS, editors. The Impact of Tumor Biology on Cancer Treatment and Multidisciplinary Strategies. Berlin: Springer Berlin Heidelberg; 2009. pp. 169-90. [DOI: 10.1007/978-3-540-74386-6_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Viertl D, Perillo-Adamer F, André PA, Ametamey SM, Ross TL, Kosinski M, Dupertuis YM, Bischof Delaloye A, Buchegger F. 18F-FLT and 125I-IdUrd uptake increase in human tumour cell lines induced by the thymidylate synthase inhibitor FdUrd. Nuklearmedizin 2012;51:163-9. [PMID: 22576273 DOI: 10.3413/Nukmed-0459-12-01] [Reference Citation Analysis]
7 Morgenroth A, Vogg AT, Mottaghy FM, Schmaljohann J. Targeted endoradiotherapy using nucleotides. Methods 2011;55:203-14. [PMID: 21782950 DOI: 10.1016/j.ymeth.2011.06.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
8 Hennequin C, Favaudon V. Quelles nouvelles drogues peut-on utiliser dans les associations chimioradiothérapie ? Cancer/Radiothérapie 1999;3:28s-41s. [DOI: 10.1016/s1278-3218(00)88220-7] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
9 Glynne-Jones R, Hadaki M, Harrison M. The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers. J Gastrointest Oncol 2013;4:264-84. [PMID: 23997939 DOI: 10.3978/j.issn.2078-6891.2013.037] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
10 Shoji H, Motegi M, Takakusagi Y, Asao T, Kuwano H, Takahashi T, Ogoshi K. Chemoradiotherapy and concurrent radiofrequency thermal therapy to treat primary rectal cancer and prediction of treatment responses. Oncol Rep 2017;37:695-704. [PMID: 27959450 DOI: 10.3892/or.2016.5300] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
11 Mouli S, Baker JC, Brown DB. Interventional Oncology Service Development. Semin Intervent Radiol 2017;34:182-6. [PMID: 28579686 DOI: 10.1055/s-0037-1601853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
12 Naida JD, Davis MA, Lawrence TS. The effect of activation of wild-type p53 function on fluoropyrimidine-mediated radiosensitization. International Journal of Radiation Oncology*Biology*Physics 1998;41:675-80. [DOI: 10.1016/s0360-3016(98)00134-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
13 Flanagan SA, Krokosky CM, Mannava S, Nikiforov MA, Shewach DS. MLH1 deficiency enhances radiosensitization with 5-fluorodeoxyuridine by increasing DNA mismatches. Mol Pharmacol 2008;74:863-71. [PMID: 18535288 DOI: 10.1124/mol.107.043349] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
14 Lawrence TS, Blackstock AW, McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol. 2003;13:13-21. [PMID: 12520460 DOI: 10.1053/srao.2003.50002] [Cited by in Crossref: 178] [Cited by in F6Publishing: 158] [Article Influence: 9.4] [Reference Citation Analysis]
15 Cuneo KC, Davis MA, Feng MU, Novelli PM, Ensminger WD, Lawrence TS. Low dose rate radiosensitization of hepatocellular carcinoma in vitro and in patients. Transl Oncol 2014;7:472-8. [PMID: 24956939 DOI: 10.1016/j.tranon.2014.05.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
16 Valdes G, Iwamoto KS. Re-evaluation of cellular radiosensitization by 5-fluorouracil: high-dose, pulsed administration is effective and preferable to conventional low-dose, chronic administration. Int J Radiat Biol 2013;89:851-62. [PMID: 23607451 DOI: 10.3109/09553002.2013.797620] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
17 Bischof M, Weber K, Blatter J, Wannenmacher M, Latz D. Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro. International Journal of Radiation Oncology*Biology*Physics 2002;52:1381-8. [DOI: 10.1016/s0360-3016(01)02794-8] [Cited by in Crossref: 54] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
18 Rich TA. Irradiation plus 5-fluorouracil: Cellular mechanisms of action and treatment schedules. Seminars in Radiation Oncology 1997;7:267-73. [DOI: 10.1016/s1053-4296(97)80025-2] [Cited by in Crossref: 18] [Article Influence: 0.7] [Reference Citation Analysis]
19 Belka C, Nieder C, Molls M. Biological Basis of Combined Radio- and Chemotherapy. In: Brown JM, Mehta MP, Nieder C, editors. Multimodal Concepts for Integration of Cytotoxic Drugs. Berlin/Heidelberg: Springer-Verlag; 2006. pp. 3-17. [DOI: 10.1007/3-540-35662-2_1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 Allen BG, Johnson M, Marsh AE, Dornfeld KJ. Base excision repair of both uracil and oxidatively damaged bases contribute to thymidine deprivation-induced radiosensitization. Int J Radiat Oncol Biol Phys 2006;65:1544-52. [PMID: 16863931 DOI: 10.1016/j.ijrobp.2006.03.051] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
21 Gmeiner WH, Jennings-Gee J, Stuart CH, Pardee TS. Thymineless death in F10-treated AML cells occurs via lipid raft depletion and Fas/FasL co-localization in the plasma membrane with activation of the extrinsic apoptotic pathway. Leuk Res 2015;39:229-35. [PMID: 25510486 DOI: 10.1016/j.leukres.2014.11.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
22 Engels B, Gevaert T, Sermeus A, De Ridder M. Current status of intensified neo-adjuvant systemic therapy in locally advanced rectal cancer. Front Oncol 2012;2:47. [PMID: 22655273 DOI: 10.3389/fonc.2012.00047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
23 Djordjevic B, Lange CS, Schwartz MS, Rotman M. Clonogenic inactivation of colon cancer-derived cells treated with 5-fluorouracil and indomethacin in hybrid spheroids. Acta Oncol. 1998;37:735-739. [PMID: 10050995 DOI: 10.1080/028418698430124] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
24 Hickey R, Vouche M, Sze DY, Hohlastos E, Collins J, Schirmang T, Memon K, Ryu RK, Sato K, Chen R, Gupta R, Resnick S, Carr J, Chrisman HB, Nemcek AA Jr, Vogelzang RL, Lewandowski RJ, Salem R. Cancer concepts and principles: primer for the interventional oncologist-part II. J Vasc Interv Radiol 2013;24:1167-88. [PMID: 23810312 DOI: 10.1016/j.jvir.2013.04.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
25 Lawrence TS, Tepper JE, Blackstock AW. Fluoropyrimidine-radiation interactions in cells and tumors. Seminars in Radiation Oncology 1997;7:260-6. [DOI: 10.1016/s1053-4296(97)80024-0] [Cited by in Crossref: 43] [Article Influence: 1.7] [Reference Citation Analysis]
26 Kleinberg L, Gibson MK, Forastiere AA. Chemoradiotherapy for localized esophageal cancer: regimen selection and molecular mechanisms of radiosensitization. Nat Clin Pract Oncol 2007;4:282-94. [PMID: 17464336 DOI: 10.1038/ncponc0796] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
27 Axelson MD, Davis MA, Ethier SP, Lawrence TS. HPV16-E7 expression causes fluorodeoxyuridine-mediated radiosensitization in SW620 human colon cancer cells. Neoplasia 1999;1:177-82. [PMID: 10933053 DOI: 10.1038/sj.neo.7900012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
28 Glynne-Jones R, Mawdsley S, Harrison M. Cetuximab and chemoradiation for rectal cancer--is the water getting muddy? Acta Oncol. 2010;49:278-286. [PMID: 20180626 DOI: 10.3109/02841860903536010] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]